Michael Peluso, MD
@michaelpelusomd.bsky.social
Long COVID and HIV cure clinician and researcher
Nice op-ed from @polybiorf.bsky.social on the need for more Long COVID trials.
PolyBio president Dr. Amy Proal outlines the direction that research must take to address long COVID in her new op-ed for @latimes.com: “The urgency of long COVID is a call to arms for government and private funders to help bring medications and protocols to the people who need them.”
Opinion: Long COVID is solvable, but we need more clinical trials
Some people may remain ill after COVID infection because the virus still lurks in their bodies. The looming question now is: Who will pay for drug development and trials?
www.latimes.com
February 16, 2025 at 10:40 PM
Nice op-ed from @polybiorf.bsky.social on the need for more Long COVID trials.
Proud to have been a part of this
@polybiorf.bsky.social effort to describe the path forward for #LongCOVID trials targeting SARS-CoV-2 persistence. We need a robust biomarker development program and to launch more trials to rigorously test treatments that target these pathways now.
@polybiorf.bsky.social effort to describe the path forward for #LongCOVID trials targeting SARS-CoV-2 persistence. We need a robust biomarker development program and to launch more trials to rigorously test treatments that target these pathways now.
1/ Cutting-edge Recommendations Provide Treatment Path for Millions of Long COVID Patients
In a new report, global experts outline key considerations to address persistent SARS-CoV-2; provide a
roadmap to test critical new long COVID therapies
polybio.org/cutting-edge...
In a new report, global experts outline key considerations to address persistent SARS-CoV-2; provide a
roadmap to test critical new long COVID therapies
polybio.org/cutting-edge...
Cutting-edge Recommendations Provide Treatment Path for Millions of Long COVID Patients - PolyBio Research Foundation
In a new report, global experts outline key considerations to address persistent SARS-CoV-2; provide a roadmap to test critical new long...
polybio.org
February 11, 2025 at 4:52 PM
Proud to have been a part of this
@polybiorf.bsky.social effort to describe the path forward for #LongCOVID trials targeting SARS-CoV-2 persistence. We need a robust biomarker development program and to launch more trials to rigorously test treatments that target these pathways now.
@polybiorf.bsky.social effort to describe the path forward for #LongCOVID trials targeting SARS-CoV-2 persistence. We need a robust biomarker development program and to launch more trials to rigorously test treatments that target these pathways now.